Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice

IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease

(2014) E. M. Castilow et al.   JOURNAL OF IMMUNOLOGY

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice

(2009) J. Kovacs-Nolan et al.   VACCINE

Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens

(2008) Yvonne Perrie et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

(2008) Maria Florencia Delgado et al.   NATURE MEDICINE

Human and bovine respiratory syncytial virus vaccine research and development

(2007) Gilles Meyer et al.   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES

Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection

(2007) J. W. Mapletoft et al.   JOURNAL OF GENERAL VIROLOGY